动脉粥样硬化（atherosclerosis，AS）是心脑血管疾病的主要病理基础，其发病机制复杂，涉及内皮损伤、脂质浸润、炎症反应、血小板聚集及血栓形成等多个环节。中医药以其整体调节和标本兼治的特色，在AS防治领域中展现出独特的优势。基于“肝郁脾虚，痰瘀毒”理论指导，中药可通过多靶点、多途径干预AS的病理进程，有望成为研究热点。结合传统中医理论与现代医学机制，系统总结中药治疗AS的研究进展，展望未来发展方向。

Atherosclerosis (AS), the primary pathological basis of cardiovascular and cerebrovascular diseases, is characterized by complex pathogenesis involving endothelial injury, lipid infiltration, inflammatory responses, platelet aggregation, and thrombus formation. In recent years, traditional Chinese medicine (TCM) has emerged as a promising approach for AS prevention and management due to its holistic regulatory effects and dual emphasis on symptom alleviation and root-cause resolution. Guided by the theory of “liver depression and spleen deficiency syndrome, phlegm-stasis-toxin”, TCM can intervene in the pathological process of AS through multiple targets and pathways, making it a promising area for future research. By integrating traditional Chinese medicine theories with modern medical mechanisms, this study systematically summarizes the research progress in the treatment of AS with TCM and prospects future development directions.

R285

中青年科技创新人才培育专项（RC230077）；中医脏象理论及应用教育部重点实验室开放基金项目（zyzx2009）；辽宁省教育厅高校基本科研项目（LJ222410162015）；国家重点基础研究发展计划（973计划）（2013CB531700）